Personalized vaccine plus standard therapy for advanced colorectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests a personalized vaccine made from your tumor's unique features, combined with a standard second-line treatment, for colorectal cancer that has worsened after the first treatment. The goal is to see if this combination can help control the cancer better than standard therapy alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have colorectal cancer that has spread or cannot be removed, and it has gotten worse after first-line treatment.
- You must be between 18 and 70 years old.
- You should be in reasonably good health, able to care for yourself, and have a life expectancy of at least 3 months.
- Your major organs (heart, liver, kidneys) and blood counts must be within acceptable ranges as determined by lab tests.
- You cannot have active infections like hepatitis, AIDS, or tuberculosis, or have used high-dose steroids in the past 2 weeks.
- You must not have had certain immunotherapies or other immune-stimulating drugs in the last 3 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a personalized vaccine made from your tumor's unique markers, combined with standard second-line treatment, for colorectal cancer that has grown after first treatment. It aims to see if this combination can help control the cancer better.
This trial tests a personalized peptide vaccine (based on your tumor's unique markers) combined with standard third-line therapy for colorectal cancer that has progressed after two prior treatments. The goal is to see if adding the vaccine can help control the cancer better.
This study tests a vaccine made from your tumor's unique proteins (neoantigens) combined with a standard third-line therapy for colorectal cancer that has worsened after two previous treatments. The goal is to see if this combination helps control the cancer better.
This trial tests a personalized immune therapy (like a custom vaccine) for people with colorectal cancer that has a positive ctDNA MRD test after surgery. It aims to use the body's own immune system to target any remaining cancer cells and prevent the cancer from coming back.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) that are trained to recognize colorectal cancer. It is for people who had surgery for colorectal cancer that spread to the liver and are now at high risk for the cancer returning.
This trial tests a custom-made T-cell treatment designed to target unique markers on your tumor. It's for people with advanced colorectal cancer who have run out of standard options or can't take them, and it aims to shrink tumors and improve survival.
Hear when a new Colorectal Cancer (CRC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.